Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Treating Lung Cancer With Vandetanib Shows Clinical Benefit When Combined With Docetaxel
When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.

CMS Proposes Payment, Policy Changes For Physicians Services To Medicare Beneficiaries In 2010
The Centers for Medicare & Medicaid Services (CMS) announced today proposed changes to policies and payment rates for services to be furnished during calendar year (CY 2010) by over 1 million physicians and nonphysician practitioners who are paid under the Medicare Physician Fee Schedule (MPFS). The MPFS sets payment rates for more than 7,000 types of services in physician offices, hospitals, and other settings.
News of the day
Doctors Who Care For Very Sick May Benefit From Pay-For-Performance
Physicians who treat patients with multiple health problems will fare well under pay-for-performance, which bases physician reimbursement on the quality of care provided, said researchers at Baylor College of Medicine and the Michael E. DeBakey Veterans Affairs Medical Center in Houston in a report in the current issue of the journal Circulation.
Mental Health

Mantle Cell Lymphoma Consortium Scientific Workshop - Report From Sixth Annual Meeting Now Available

Almost 60 mantle cell lymphoma (MCL) specialists from around the world gathered in Atlanta, GA for the Lymphoma Research Foundation"s (LRF) Sixth Annual Mantle Cell Lymphoma Consortium (MCLC) Scientific Workshop. Attendees heard presentations addressing several key issues including the biology of MCL, prognostic indicators, new molecular targets, chemoimmunotherapy, transplantation and novel therapeutic approaches. The MCLC was established by the Lymphoma Research Foundation (LRF) in 2005 to accelerate the pace of mantle cell lymphoma research. Attendees to this year"s workshop included: LRF MCLC members, including LRF MCL grant recipients as well as other scientific investigators conducting cutting-edge research. As in the past, this year"s meeting provided a unique opportunity for experts to report on their research findings and exchange ideas on how to best improve treatment options for individuals living with MCL. Those in attendance heard 17 oral presentations, viewed 9 poster presentations and participated in 6 roundtable discussions covering areas such as: Clinical Trails for Younger Patients, Epigenetic Studies in MCL and Cell Cycle Targets for MCL. About Mantle Cell Lymphoma Mantle cell lymphoma (MCL) is a B-cell lymphoma that gets its name because mantle cell tumors are composed of cells that come from the "mantle" zone of the lymph node. Frequently, MCL is diagnosed as a stage 4 disease, often present in lymphnodes above and below the diaphragm and in most cases involves the gastrointestinal tract and bone marrow. MCL is a relatively rare disease, constituting only about 6 percent of all NHL cases in the United States (i.e., only about 3,000 cases per year in the U.S.). This lymphoma usually affects men over the age of 60. Lymphoma Research Foundation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009